Diagnostic testing companies are aiming to deliver 25 million COVID-19 tests by the end of April and increase that number by the end of May, the head of medtech trade group AdvaMed said today.
But the number of available tests is less important than the U.S. healthcare system’s capacity to process all the tests that will be needed to diagnose COVID-19, AdvaMed CEO Scott Whitaker said in a telephone press conference this morning.
“We have millions of tests but our ability to process them is really what matters,” Whitaker said. “We can see the stretch and strain that it’s putting on the system right now. The same thing is happening in our laboratories.”